SL
FULC icon

Siren LLC’s Fulcrum Therapeutics FULC Stock Holding History

Siren LLC’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18M Buy
2,350,000
+400,000
+21% +$3.71M 0.5% 42
2025
Q4 		$22.1M Buy
+1,950,000
New +$19.8M 0.66% 38

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Siren LLC's FULC Position: Q1 2026 in Review

Siren LLC increased its Fulcrum Therapeutics (FULC) stake by 21% in Q1 2026, buying an estimated $3.71M and bringing the position to 2,350,000 shares worth $18M. The position accounts for 0.5% of the portfolio, ranked #42.

Siren LLC first reported a position in FULC in Q4 2025 and has held it in 2 quarters since. The position peaked at $22.1M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Siren LLC held 2,350,000 shares of Fulcrum Therapeutics worth $18M as of Q1 2026.
  • Siren LLC bought 400,000 Fulcrum Therapeutics shares in Q1 2026, an estimated $3.71M.
  • Fulcrum Therapeutics made up 0.5% of Siren LLC's portfolio in Q1 2026, its #42 holding.
  • Siren LLC first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Siren LLC's Fulcrum Therapeutics position peaked at $22.1M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.